SCHEMBL6296223

SCHEMBL6296223

Cc1ccc(S(=O)(=O)Sc2cc3sc(N)nc3cc2C(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
MAPT P10636 3/20 0.48
LMNA P02545 3/20 0.48
HSD17B10 Q99714 2/20 0.48
HTT P42858 2/20 0.48
USP2 O75604 1/20 0.48
HPGD P15428 3/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.41
SCN4A P35499 1/20 0.41
CYP3A4 P08684 3/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
GAA P10253 2/20 0.38
DNMT1 P26358 1/20 0.38
VDR P11473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302939 0.82 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTLMNAHSD17B10
SCHEMBL5881069 0.80 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTLMNAHSD17B10
SCHEMBL6296294 0.79 DNMT1 (0.39) ALDH1A1SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL6296938 0.78 DNMT1 (0.47) ALDH1A1LMNAHTTKMT2AGAA
SCHEMBL6297760 0.74 HTT (0.38) ALDH1A1SMN1; SMN2MAPTLMNAHSD17B10
SCHEMBL6606825 0.73 DNMT1 (0.51) ALDH1A1LMNAGAADNMT1CA2
SCHEMBL6296484 0.73 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2MAPTLMNAHSD17B10
SCHEMBL6296239 0.70 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2MAPTHSD17B10HTT
SCHEMBL6296568 0.69 KMT2A (0.44) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL6296709 0.66 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2MAPTLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US claimed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP claimed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO claimed
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD ALDH1A1 1219/4885SMN1; SMN2 4359/4885MAPT 1327/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD ALDH1A1 1309/4885SMN1; SMN2 4356/4885MAPT 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.